$SMLR
Semler Scientific, Inc.

2021 Q1 Form 10-Q Financial Statement

#000155837021006364 Filed on May 07, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q3 2020 Q1
Revenue $13.18M $10.73M $9.430M
YoY Change 39.8% 20.5% 39.48%
Cost Of Revenue $1.579M $820.0K $850.0K
YoY Change 85.76% -15.81% -5.13%
Gross Profit $11.60M $9.907M $8.580M
YoY Change 35.24% 24.96% 46.29%
Gross Profit Margin 88.02% 92.36% 90.99%
Selling, General & Admin $4.892M $3.680M $4.286M
YoY Change 14.14% -12.38% 24.52%
% of Gross Profit 42.16% 37.15% 49.95%
Research & Development $693.0K $672.0K $842.0K
YoY Change -17.7% 8.91% 47.98%
% of Gross Profit 5.97% 6.78% 9.81%
Depreciation & Amortization $43.00K $32.00K $31.00K
YoY Change 38.71% -15.79% -78.32%
% of Gross Profit 0.37% 0.32% 0.36%
Operating Expenses $4.892M $3.680M $4.286M
YoY Change 14.14% -12.38% 6.86%
Operating Profit $6.019M $5.555M $3.452M
YoY Change 74.36% 78.56% 86.19%
Interest Expense $3.000K $2.000K $2.000K
YoY Change 50.0% -200.0%
% of Operating Profit 0.05% 0.04% 0.06%
Other Income/Expense, Net $1.000K $40.00K -$2.000K
YoY Change -150.0% -1433.33%
Pretax Income $6.020M $5.595M $3.450M
YoY Change 74.49% 80.02% 86.08%
Income Tax $1.143M $729.0K $777.0K
% Of Pretax Income 18.99% 13.03% 22.52%
Net Earnings $4.877M $4.866M $2.673M
YoY Change 82.45% -37.45% 44.17%
Net Earnings / Revenue 36.99% 45.36% 28.35%
Basic Earnings Per Share $0.73 $0.74 $0.41
Diluted Earnings Per Share $0.60 $0.61 $0.33
COMMON SHARES
Basic Shares Outstanding 6.711M 6.579M 6.533M
Diluted Shares Outstanding 8.169M 8.039M 8.066M

Balance Sheet

Concept 2021 Q1 2020 Q3 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.48M $16.79M $11.21M
YoY Change 136.12% 96.59% 146.79%
Cash & Equivalents $26.48M $16.79M $11.21M
Short-Term Investments
Other Short-Term Assets $1.769M $1.530M $688.0K
YoY Change 157.12% 458.39% 205.78%
Inventory $639.0K
Prepaid Expenses $611.0K $900.0K
Receivables $4.399M $3.455M $1.581M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $33.29M $21.78M $13.48M
YoY Change 146.87% 80.18% 84.65%
LONG-TERM ASSETS
Property, Plant & Equipment $351.0K $258.0K $2.375M
YoY Change -85.22% -87.39% 36.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $3.051M
YoY Change
Other Assets $392.0K $432.0K $3.778M
YoY Change -89.62% -90.86% 25086.67%
Total Long-Term Assets $7.361M $6.269M $6.153M
YoY Change 19.63% -7.4% 251.0%
TOTAL ASSETS
Total Short-Term Assets $33.29M $21.78M $13.48M
Total Long-Term Assets $7.361M $6.269M $6.153M
Total Assets $40.65M $28.05M $19.64M
YoY Change 107.0% 48.74% 116.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $470.0K $336.0K $377.0K
YoY Change 24.67% -49.78% 46.69%
Accrued Expenses $3.477M $4.277M $2.030M
YoY Change 71.28% 57.01% 12.4%
Deferred Revenue $1.049M $960.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.073M $5.651M $3.820M
YoY Change 32.8% 19.04% 32.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $305.0K $345.0K $0.00
YoY Change 4212.5% -100.0%
Total Long-Term Liabilities $305.0K $345.0K $0.00
YoY Change 4212.5% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.073M $5.651M $3.820M
Total Long-Term Liabilities $305.0K $345.0K $0.00
Total Liabilities $5.378M $5.996M $3.820M
YoY Change 40.79% 26.1% 32.0%
SHAREHOLDERS EQUITY
Retained Earnings $12.55M $2.280M
YoY Change
Common Stock $7.000K $7.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $25.00K $25.00K
Shareholders Equity $35.27M $22.05M $15.82M
YoY Change
Total Liabilities & Shareholders Equity $40.65M $28.05M $19.64M
YoY Change 107.0% 48.74% 116.85%

Cashflow Statement

Concept 2021 Q1 2020 Q3 2020 Q1
OPERATING ACTIVITIES
Net Income $4.877M $4.866M $2.673M
YoY Change 82.45% -37.45% 44.17%
Depreciation, Depletion And Amortization $43.00K $32.00K $31.00K
YoY Change 38.71% -15.79% -78.32%
Cash From Operating Activities $4.606M $3.542M $3.703M
YoY Change 24.39% -24.8% 117.44%
INVESTING ACTIVITIES
Capital Expenditures $133.0K -$99.00K $91.00K
YoY Change 46.15% -72.95% -119.96%
Acquisitions
YoY Change
Other Investing Activities -$400.0K
YoY Change
Cash From Investing Activities -$216.0K -$499.0K -$233.0K
YoY Change -7.3% 36.34% -48.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.000K 104.0K 3.000K
YoY Change 200.0% 550.0% -76.92%
NET CHANGE
Cash From Operating Activities 4.606M 3.542M 3.703M
Cash From Investing Activities -216.0K -499.0K -233.0K
Cash From Financing Activities 9.000K 104.0K 3.000K
Net Change In Cash 4.399M 3.147M 3.473M
YoY Change 26.66% -27.82% 175.63%
FREE CASH FLOW
Cash From Operating Activities $4.606M $3.542M $3.703M
Capital Expenditures $133.0K -$99.00K $91.00K
Free Cash Flow $4.473M $3.641M $3.612M
YoY Change 23.84% -28.27% 67.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001554859
CY2021Q1 dei Trading Symbol
TradingSymbol
smlr
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PrepaidExpenseAndOtherAssetsCurrent
CY2021Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2021Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PrepaidExpenseAndOtherAssetsCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-36305
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
SEMLER SCIENTIFIC, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1367393
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2340-2348 Walsh Avenue, Suite 2344
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Santa Clara
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95051
CY2021Q1 dei City Area Code
CityAreaCode
877
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
774-4211
CY2021Q1 dei Security12b Title
Security12bTitle
N/A
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6725226
CY2021Q1 us-gaap Revenues
Revenues
13183000
CY2020Q1 us-gaap Revenues
Revenues
9430000
CY2021Q1 us-gaap Cost Of Revenue
CostOfRevenue
1579000
CY2020Q1 us-gaap Cost Of Revenue
CostOfRevenue
850000
CY2021Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
693000
CY2020Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
842000
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2816000
CY2020Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2695000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2076000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1591000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
7164000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
5978000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
6019000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
3452000
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
3000
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6020000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3450000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1143000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
777000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
4877000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
2673000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.73
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6710990
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6533369
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.60
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8169375
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8065813
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26478000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22079000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
61000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
61000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4399000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2808000
CY2021Q1 us-gaap Inventory Net
InventoryNet
639000
CY2020Q4 us-gaap Inventory Net
InventoryNet
340000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1769000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1376000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
33285000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
26603000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1828000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1941000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
351000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
261000
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
392000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
418000
CY2021Q1 us-gaap Long Term Investments
LongTermInvestments
3051000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
3051000
CY2021Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
1739000
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
2365000
CY2021Q1 us-gaap Assets
Assets
40646000
CY2020Q4 us-gaap Assets
Assets
34639000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
470000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
677000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3477000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2798000
CY2021Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1049000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
963000
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
77000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
76000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5073000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4514000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
305000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
332000
CY2021Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
305000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
332000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6745806
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6725422
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6720806
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6700422
CY2021Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
25000
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
25000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22711000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22113000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
12550000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
7673000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
35268000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
29793000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40646000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34639000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
13073000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
67000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
2673000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
15816000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
29793000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
537000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
52000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
4877000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
35268000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
4877000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
2673000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
155000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
159000
CY2021Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
626000
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
721000
CY2021Q1 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-83000
CY2020Q1 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-66000
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5000
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
31000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
589000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
67000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1595000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1875000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
299000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
39000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
393000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
457000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-26000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-207000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
39000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
679000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1466000
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-26000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
86000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
34000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4606000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3703000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
133000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
91000
CY2021Q1 us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
83000
CY2020Q1 us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
142000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-216000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-233000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4399000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3473000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22079000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7741000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26478000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11214000
CY2021Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">1.           Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Semler Scientific, Inc., a Delaware corporation (“Semler” or “the Company”), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 9, 2021 (the “Annual Report”). In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Reclassification of Prior Year Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">COVID-19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On January 30, 2020, the World Health Organization (“WHO”) declared the recent novel coronavirus (COVID-19) outbreak a global health emergency, which prompted national, state and local governments to begin putting actions in place to slow the spread of COVID-19. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic. The outbreak of COVID-19 resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world. While restrictions began to ease in the second quarter and activities began to resume, recent outbreaks could lead to restrictions being reimplemented. In the first half of 2020, the Company’s revenues, primarily from variable-fee licenses, were negatively impacted by the COVID-19 pandemic. In the second half of 2020 and the first quarter of 2021, the Company’s revenues, primarily from variable-fee licenses, rebounded to and even exceeded pre-COVID-19 levels. The extent and duration of the pandemic is unknown, and the future effects on the Company’s business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recently Issued Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>, which simplifies the accounting for income taxes by removing certain exceptions to the general principles for income taxes. This update is effective for the Company’s annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted the new standard on January 1, 2021 and determined that the adoption of this new accounting guidance did not have a material impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In January 2020, the FASB issued ASU No. 2020-01, <i style="font-style:italic;">Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).</i> The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. This ASU is effective for fiscal years beginning after December 15, 2020. The Company adopted the new standard on January 1, 2021 and determined that the adoption of this new accounting guidance did not have an impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In October 2020, the FASB issued ASU No. 2020-10, <i style="font-style:italic;">Codification Improvements</i>. This ASU is the final update of the 2019 proposed ASU, Codification Improvements, of which various topics in the Codification are amended, clarified, simplified, or otherwise modified to improve the Codification. The amendments in Section B of this ASU improve the Codification by ensuring that all guidance that requires or provides an option for an entity to provide information in the notes to financial statements is codified in the disclosure section of the Codification. The amendments in Section C of this ASU are varied in nature and may affect the application of the guidance in cases which the original guidance may have been unclear. The amendments in Sections B and C of this ASU are effective for the Company’s annual periods beginning after December 15, 2020, and the amendments should be applied retrospectively, and should be applied at the beginning of the period that includes the adoption date. The Company adopted the new standard on January 1, 2021 and determined that the adoption of this new accounting guidance did not have a material impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“Topic 326”).</i> This ASU requires timelier recording of credit losses on loans and other financial instruments held. Instead of reserves based on a current probability analysis, Topic 326 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. All organizations will now use forward-looking information to better inform their credit loss estimates. Topic 326 requires enhanced disclosures regarding significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. These disclosures include qualitative and quantitative requirements that provide information about the amounts recorded in the financial statements. In addition, Topic 326 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. In April 2019, the FASB issued ASU No. 2019-04, <i style="font-style:italic;">Codification Improvements to Topic 326 Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825,</i> <i style="font-style:italic;">Financial Instruments</i>, to introduce amendments which will affect the recognition and measurement of financial instruments, including derivatives and hedging. In May 2019, the FASB issued ASU No. 2019-05, <i style="font-style:italic;">Financial Instruments – Credit Losses (Topic 326); </i>Targeted Transition Relief. The amendments in this ASU provide entities that have certain instruments within the scope of Subtopic 326-20 with an option to irrevocably elect the fair value option in Subtopic 825-10, applied on an instrument-by-instrument basis for eligible instruments upon adoption of Topic 326. This standard and related amendments are effective for the Company’s fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company does not anticipate this new standard will have a material impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In March 2020, the FASB issued ASU No. 2020-03, <i style="font-style:italic;">Codification Improvements to Financial Instruments</i>. This ASU improves and clarifies various financial instruments topics, including the current expected credit losses standard issued in 2016 (ASU No. 2016-13). The ASU includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The amendments have different effective dates. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company's financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In March 2020, the FASB issued ASU No. 2020-04, <i style="font-style:italic;">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>. This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates and, particularly, the risk of cessation of the London Interbank Offered Rate, regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to be discontinued. The ASU can be adopted no later than December 1, 2022, with early adoption permitted. The Company has not yet adopted this ASU and is evaluating the effect of adopting this new accounting guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2020, the FASB issued ASU No. 2020-06, <i style="font-style:italic;">Debt--Debt with Conversion and Other Options (Subtopic 470-20) </i>and Derivatives and Hedging— Contracts in Entity's Own Equity (Subtopic 815-40). The amendments in this ASU affect entities that issue convertible instruments and/or contracts in an entity's own equity. For contracts in an entity's own equity, the contracts primarily affected </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">are freestanding instruments and embedded features that are accounted for as derivatives under the current guidance because of failure to meet the settlement conditions of the derivatives scope exception related to certain requirements of the settlement assessment. The FASB simplified the settlement assessment by removing the requirements (1) to consider whether the contract would be settled in registered shares, (2) to consider whether collateral is required to be posted, and (3) to assess shareholder rights. Those amendments also affect the assessment of whether an embedded conversion feature in a convertible instrument qualifies for the derivatives scope exception. Additionally, the amendments in this ASU affect the diluted EPS calculation for instruments that may be settled in cash or shares and for convertible instruments. The ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock by eliminating the beneficial conversion feature model and cash conversion model. As compared with current GAAP, more convertible debt instruments will be reported as a single liability instrument and more convertible preferred stock as a single equity instrument. The interest rate of more convertible debt instruments will be closer to the coupon interest rate. This ASU is effective for the Company’s fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company has not yet adopted this ASU and is evaluating the effect of adopting this new accounting guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In January 2021, the FASB issued ASU No. 2021-01, <i style="font-style:italic;">Reference Rate Reform (Topic 848)</i>. This ASU clarifies the scope of Topic 848 so that derivatives affected by the discounting transition due to reference rate reform initiatives are explicitly eligible for certain optional expedients and exceptions in Topic 84. In addition, to efficiently address another emerging issue related reference rate reform and respond to stakeholder feedback on the proposed feedback on the proposed update on this project, the Board decided to clarify that a receive-variable-rate, pay-variable-rate cross-currency interest rate swap may be considered an eligible hedging instrument in a net investment hedge if both legs of the swap do not have the same repricing intervals and dates as of the result of reference rate reform. The amendments in this update are elective and apply to all entities that have derivative instruments that use an interest rate for margining, discounting, or contract price alignment that is modified as a result of reference rate reform. The amendments also optionally apply to all entities that designate receive-variable-rate, pay-variable-rate cross-currency interest rate swaps as hedging instruments in net investment hedges that are modified as a result of reference rate reform. An entity may elect to apply the amendments in this update on a full retrospective basis as of any date from the beginning of an interim period that includes or is subsequent to March 12, 2020, or on a prospective basis to new modifications from any date within an interim period that includes or is subsequent to the date of the issuance of a final update, up to the date that financial statements are available to be issued. The amendments in this update do not apply to contract modifications made after December 31, 2022, new hedging relationships entered into after December 31, 2022, and existing hedging relationships evaluated for effectiveness in periods after December 31, 2022, except for hedging relationships existing as of December 31, 2022, that apply certain optional expedients in which the accounting effects are recorded through the end of the hedging relationship (including periods after December 31, 2022). The Company has not yet adopted this ASU and is evaluating the effect of adopting this new accounting guidance.<b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">​</span></p>
CY2021Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Reclassification of Prior Year Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.</p>
CY2021Q1 smlr Revenue Recognition From Variable License Fee Contracts
RevenueRecognitionFromVariableLicenseFeeContracts
5658000
CY2020Q1 smlr Revenue Recognition From Variable License Fee Contracts
RevenueRecognitionFromVariableLicenseFeeContracts
2703000
CY2021Q1 smlr Revenue Recognition From Sales Of Hardware And Equipment Accessories
RevenueRecognitionFromSalesOfHardwareAndEquipmentAccessories
331000
CY2020Q1 smlr Revenue Recognition From Sales Of Hardware And Equipment Accessories
RevenueRecognitionFromSalesOfHardwareAndEquipmentAccessories
270000
CY2020Q3 smlr Purchase Of Product Inventory
PurchaseOfProductInventory
1200000
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
900000
CY2021Q1 smlr Product Inventory Prepaid Purchases Recognized
ProductInventoryPrepaidPurchasesRecognized
289000
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
611000
CY2020Q3 smlr Distribution Agreement Renewal Term
DistributionAgreementRenewalTerm
P4Y
CY2021Q1 us-gaap Other Inventory
OtherInventory
356000
CY2021Q1 us-gaap Inventory Net
InventoryNet
639000
CY2020Q4 us-gaap Inventory Net
InventoryNet
340000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7194000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6457000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
3266000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
3407000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
1438000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
1466000
CY2021Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1828000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1941000
CY2021Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
113000
CY2020Q1 us-gaap Depreciation Nonproduction
DepreciationNonproduction
128000
CY2021Q1 smlr Accumulated Depreciation Reduction For Returned Items
AccumulatedDepreciationReductionForReturnedItems
141000
CY2020Q1 smlr Accumulated Depreciation Reduction For Returned Items
AccumulatedDepreciationReductionForReturnedItems
65000
CY2021Q1 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-83000
CY2020Q1 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-66000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
919000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
786000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
568000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
525000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
351000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
261000
CY2021Q1 us-gaap Depreciation
Depreciation
43000
CY2020Q1 us-gaap Depreciation
Depreciation
31000
CY2021Q1 us-gaap Long Term Investments
LongTermInvestments
3051000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
3051000
CY2021Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
90000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
93000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
71000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1749000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1524000
CY2021Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1281000
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
861000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
447000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
413000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3477000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2798000
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P61M
CY2021Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P4Y6M
CY2021Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
false
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
44000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
17000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
405000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
64000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
87000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
23000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
382000
CY2021Q1 smlr Operating Lease Expenses In Excess Of Cash Payments
OperatingLeaseExpensesInExcessOfCashPayments
9000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
373000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
373000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
77000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
305000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
399000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
75000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
332000
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P61M
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
5400
CY2021Q1 smlr Share Based Compensation Arrangement By Share Based Payment Award Number Of Non Employees
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNonEmployees
1
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
537000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1451420
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.25
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y10M28D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
131714000
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15000
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.61
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1436420
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.28
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y8M12D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
149705000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1414285
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.20
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y8M1D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
147503000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
132000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y8M15D
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
589000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
589000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67000
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1899
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2252
CY2021Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2252
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
342000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
341000
CY2021Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6710990
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4877000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.73
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6533369
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2673000
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2021Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
73497
CY2021Q1 smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
CY2020Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
69715
CY2020Q1 smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
CY2021Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1384888
CY2021Q1 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
CY2020Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1462729
CY2020Q1 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8169375
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
4877000
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.60
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8065813
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2673000
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0

Files In Submission

Name View Source Status
0001558370-21-006364-index-headers.html Edgar Link pending
0001558370-21-006364-index.html Edgar Link pending
0001558370-21-006364.txt Edgar Link pending
0001558370-21-006364-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
smlr-20210331.xsd Edgar Link pending
smlr-20210331x10q.htm Edgar Link pending
smlr-20210331x10q_htm.xml Edgar Link completed
smlr-20210331xex31d1.htm Edgar Link pending
smlr-20210331xex31d2.htm Edgar Link pending
smlr-20210331xex32d1.htm Edgar Link pending
smlr-20210331_cal.xml Edgar Link unprocessable
smlr-20210331_def.xml Edgar Link unprocessable
smlr-20210331_lab.xml Edgar Link unprocessable
smlr-20210331_pre.xml Edgar Link unprocessable